← Leaderboards
James Jeffrey Sahn
4e Therapeutics Inc.
$7,126,294
Attributed
$7,126,294
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2019–23$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,126,294 · 1
By mechanism
U44$7,126,294 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToGrowth FactorAblationDrug KineticsExperimental StudyGeneticBasic ScienceAntineoplastic AgentsBindingAreaAttenuatedEukaryotic Initiation FactorsBrainCancer PainCancer TypeCellsBehavioralChronic PainClinical CandidateClinical DevelopmentBiological AvailabilityCytokineDoseImmune Response
Grant awards (5)
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$2,195,014
U44 · FY2023 · NS · contact PI
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$1,940,921
U44 · FY2022 · NS · contact PI
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$1,439,283
U44 · FY2021 · NS · contact PI
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$61,625
U44 · FY2020 · NS · contact PI
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$1,489,451
U44 · FY2019 · NS · contact PI